Multiple anti-HER2 agents, including trastuzumab, HER2-based drug combinations, and HER2-directed antibody-drug conjugates, are now under investigation for treating patients with HER2-overexpressing biliary tract cancer, based on their promising efficacy in prior small retrospective studies (52). Here, ERBB2 is linked to biliary tract cancer.